Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
52
INSM Quote, Financials, Valuation and Earnings
Last price:
$164.92
Seasonality move
:
7.06%
Day range:
$147.26 - $163.14
52-week range:
$60.40 - $212.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
52.80x
P/B ratio:
46.47x
Volume:
4.9M
Avg. volume:
2.6M
1-year change:
92.06%
Market cap:
$34.3B
Revenue:
$606.4M
EPS (TTM):
-$6.40
Analysts' Opinion
-
Consensus RatingInsmed, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 17 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $213.11, Insmed, Inc. has an estimated upside of 33.15% from its current price of $161.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $162.00 representing -0.62% downside risk from its current price of $161.00.
Fair Value
-
According to the consensus of 18 analysts, Insmed, Inc. has 33.15% upside to fair value with a price target of $213.11 per share.
INSM vs. S&P 500
-
Over the past 5 trading days, Insmed, Inc. has overperformed the S&P 500 by 8.06% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Insmed, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Insmed, Inc. has grown year-over-year revenues for 19 quarters straight. In the most recent quarter Insmed, Inc. reported revenues of $263.8M.
Earnings Growth
-
Insmed, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Insmed, Inc. reported earnings per share of -$1.54.
Enterprise value:
33.7B
EV / Invested capital:
22.52x
Price / LTM sales:
52.80x
EV / EBIT:
--
EV / Revenue:
55.51x
PEG ratio (5yr expected):
-1.72x
EV / Free cash flow:
-33.74x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$477.5M
Return On Assets:
-58.39%
Net Income Margin (TTM):
-210.54%
Return On Equity:
-192.35%
Return On Invested Capital:
-77.98%
Operating Margin:
-94.64%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $305.2M | $363.7M | $606.4M | $104.4M | $263.8M | |
| Gross Profit | $234.6M | $272.9M | $477.5M | $77M | $217.7M | |
| Operating Income | -$680.9M | -$786.6M | -$994.8M | -$245.2M | -$249.7M | |
| EBITDA | -$661.9M | -$775.6M | -$978.3M | -$242.5M | -$244.1M | |
| Diluted EPS | -$5.35 | -$5.59 | -$6.40 | -$1.32 | -$1.54 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $837M | $1.3B | $929.1M | $1.6B | $1.8B | |
| Total Assets | $1.2B | $1.7B | $1.3B | $2B | $2.3B | |
| Current Liabilities | $135.2M | $190.2M | $225.6M | $297.5M | $468.9M | |
| Total Liabilities | $833M | $1.6B | $1.7B | $1.7B | $1.5B | |
| Total Equity | $410.5M | $88M | -$331.9M | $285.4M | $739M | |
| Total Debt | $602.7M | $1.3B | $1.4B | $1.3B | $736.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$536.2M | -$683.9M | -$935M | -$196M | -$247.6M | |
| Cash From Investing | -$223.6M | -$583.2M | -$64.6M | $131.8M | $389.4M | |
| Cash From Financing | $168.4M | $1.3B | $954.1M | $159.3M | $33.9M | |
| Free Cash Flow | -$549.5M | -$705.8M | -$997.6M | -$202.8M | -$294.2M | |
INSM
Sector
Market Cap
$34.3B
$25.2M
Price % of 52-Week High
75.68%
49.83%
Dividend Yield
0%
0%
Shareholder Yield
-2.36%
-1.77%
1-Year Price Total Return
92.06%
-21.9%
Beta (5-Year)
1.105
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$150.51
200-day SMA
Buy
Level
$139.54
Bollinger Bands (100)
Sell
Level
154.38 - 192.92
Chaikin Money Flow
Buy
Level
182.4M
20-day SMA
Buy
Level
$153.90
Relative Strength Index (RSI14)
Buy
Level
54.40
ADX Line
Buy
Level
28.43
Williams %R
Sell
Level
-10.6203
50-day SMA
Sell
Level
$168.11
MACD (12, 26)
Sell
Level
-4.39
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
268.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.634)
Sell
CA Score
(Annual)
Level (-3.6447)
Sell
Beneish M-Score
(Annual)
Level (-1.7723)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.3191)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Stock Forecast FAQ
In the current month, INSM has received 17 Buy ratings 1 Hold ratings, and 0 Sell ratings. The INSM average analyst price target in the past 3 months is $213.11.
-
Where Will Insmed, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Insmed, Inc. share price will rise to $213.11 per share over the next 12 months.
-
What Do Analysts Say About Insmed, Inc.?
Analysts are divided on their view about Insmed, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Insmed, Inc. is a Sell and believe this share price will drop from its current level to $162.00.
-
What Is Insmed, Inc.'s Price Target?
The price target for Insmed, Inc. over the next 1-year time period is forecast to be $213.11 according to 18 Wall Street analysts, 17 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is INSM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Insmed, Inc. is a Buy. 17 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of INSM?
You can purchase shares of Insmed, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Insmed, Inc. shares.
-
What Is The Insmed, Inc. Share Price Today?
Insmed, Inc. was last trading at $164.92 per share. This represents the most recent stock quote for Insmed, Inc.. Yesterday, Insmed, Inc. closed at $161.00 per share.
-
How To Buy Insmed, Inc. Stock Online?
In order to purchase Insmed, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get INSM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
INSM
Sector
P/E ratio
--
23.30x
PEG ratio
-1.72x
-0.01x
P/B ratio
46.47x
1.78x
Price / LTM sales
52.80x
1.55x
Growth Metrics
INSM
Sector
Revenue growth
152.62%
3.69%
Earnings growth
-16.86%
9.95%
Revenue (5-year growth)
29.83%
6.38%
Earnings forecast
-$1.17
-$0.19
Profitability
INSM
Sector
Profitability FY 2025
$477.5M
$2.6M
Return on invested capital
-77.98%
-33.25%
Return on assets
-58.39%
-29.67%
Return on equity
-192.35%
-38.66%
Earnings Date
Last Earnings Date
Feb
19
Next Earnings Date
Feb
20
Estimated Next Earnings Date
May
22
Balance Sheet
INSM
Sector
Total cash
$1.4B
$25.1M
Short term investments
$878.8M
$24M
Total assets
$2.3B
$72.5M
Long term debt
$736.7M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
